Clinical Trials for
Retina Diseases & Problems

There has never been a more exciting time for patients suffering from wet Age-Related Macular Degeneration (nARMD), Diabetic Retinopathy (DR), or Retinal Vein Occlusions (RVO). Laser treatment was once the only treatment option available to destroy abnormal blood vessel growth responsible for severe visual loss in patients with nARMD and DR and target areas of leakage that lead to swelling of the retina in DR and RVO. The effectiveness was severely limited by poor visual results and a tendency for the blood vessels to grow back or leakage to recur.

Current therapy with powerful medicines delivered directly into the eye, have all but replaced traditional laser therapy. These treatments are not only extremely effective in preventing further vision loss, but can offer a chance of improving vision. We could not have come this far in the treatment of nARMD, DR, and RVO were it not for CLINICAL TRIALS which carefully evaluated these medications and proved that they were both SAFE and EFFECTIVE. Were it not for the many dedicated patients who volunteered to take part in these trials, the general population and future generations would not have these wonderful therapies available today.

Our current research has shifted to the treatment of patients with the dry form of ARMD. We are currently enrolling patients in trials that are investigating new medicines and also the latest in gene therapy. For patients with nARMD and DR we are investigating an implanted drug delivery system (Port Delivery System) designed to permit patients to be treated at 6 month intervals.

As part of The Retina Care Center’s commitment to offer our patients the most sophisticated retinal care, we recognize that not all patients respond well to traditional therapy. We also have patients who may be looking for better results than what standard therapy can offer. Regardless of motivation, it is this type of individual that might be interested in participating in a clinical trial investigating a new medication, surgical procedure, or treatment strategy.

Although clinical trials do not guarantee a cure, a better visual outcome, or even treatment with the study medication in question, patients understand that their commitment to these investigations may lead to the approval of even better treatments for retinal diseases such as ARMD, DR, and RVO. These individuals share the common goal of lessening the burden of blindness for current and future generations.

The Retina Care Center is currently enrolling patients for the following major Clinical Trials (diseases in parenthesis):

  • PAGODA-Ranibizumab Port Delivery System (Diabetic Macular Edema)
  • GALLEGO-RO7171009 (Geographic Atrophy Secondary to Age-Related Macular Degeneration)
  • IONIS-IONIS-FB-LRx (Geographic Atrophy Secondary to Age-Related Macular Degeneration)
  • PAVILION – Ranibizumab Port Delivery System (NPDR)
  • iSee2008 – Zimura (Geographic Atrophy Secondary to Age-Related Macular Degeneration)
  • 20170542 – ABP 938 (Neovascular Age Related Macular Degeneration)
  • PULSAR – High Dose Aflibercept (Neovascular Age Related Macular Degeneration)
  • HORIZON – GT005 (Geographic Atrophy Secondary to Age-Related Macular Degeneration)
  • EXPLORE – GT005 (Geographic Atrophy Secondary to Age-Related Macular Degeneration)

The Retina Care Center is currently actively participating but no longer enrolling in the following major Clinical Trials (diseases in parenthesis):

  • RECLAIM2-Elamipretide (Geographic Atrophy Secondary to Age-Related Macular Degeneration)
  • OAKS-APL-2 (Geographic Atrophy Secondary to Age-Related Macular Degeneration)
  • LUCERNE-Faricimab (Wet Age-Related Macular Degeneration)
  • YOSEMITE-Faricimab (Diabetic Macular Edema)
  • ARCHWAY-Ranibizumab Port Delivery System (Wet Age-Related Macular Degeneration)
  • OPH2003-Zimura (Geographic Atrophy secondary to Age-Related Macular Degeneration)
  • PHOTON – High Dose Aflibercept (Diabetic Macular Edema)
  • PORTAL – Ranibizumab Port Delivery System (Neovascular Age Related Macular Degeneration)
  • Rhone-X – Faricimab (Diabetic Macular Edema)

The Retina Care Center has completed participation in the following major Clinical Trials (diseases in parenthesis):

  • ALTISSIMO-Sunitinib Malate (GB-102) (Wet Age-Related Macular Degeneration)
  • STAIRWAY-Faricimab (Wet Age-Related Macular Degeneration)
  • SEQUOIA-Abicipar Pegol (Wet Age-Related Macular Degeneration)
  • RUBY-Nesvacumab (Diabetic Macular Edema)
  • PANORAMA-Aflibercept (Nonproliferative Diabetic Retinopathy)
  • OHR-Squalamine Lactate (Wet Age-Related Macular Degeneration)
  • SPECTRI-Lampalizumab (Advanced Dry Age-Related Macular Degeneration)
  • ECLIPSE-Fovista (Wet Age-Related Macular Degeneration)
  • HAWK-Brolucizumab (Wet Age-Related Macular Degeneration)
  • CAPELLA-REGN2176 (Wet Age-Related Macular Degeneration)
  • EMERGE-hI-con1 (Wet Age-Related Macular Degeneration)
  • VIBRANT (Macular Edema due to Branch Retinal Vein Occlusion)
  • COPERNICUS (Macular Edema due to Central Retinal Vein Occlusion)
  • VISTA (Macular Edema due to Diabetic Retinopathy)
  • VIEW1 (Wet Age-Related Macular Degeneration)

The Retina Care Center is proud to announce our upcoming major Clinical Trials (diseases in parenthesis):

  • ATMOSPHERE – RGX 314 (Neovascular Age Related Macular Degeneration)
  • BELVEDERE – Ranibizumab Port Delivery System (Neovascular Age Related Macular Degeneration)
  • ShORe – OPT-302 (Neovascular Age Related Macular Degeneration)

Frequently Asked Questions about Clinical Trials is available here to download with details about participating in a clinical trial at the Retina Care Center.  Clinical Trial FAQ Patient Handout

Please ask any staff member if you are interested in learning more about these Clinical Trials and whether you might be eligible for participation.